Articles On Imugene (ASX:IMU)

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Imugene (ASX: IMU) has unveiled “impressive” pre-clinical in vivo anti-tumour responses using its onCARlytics technology in combination with Eureka Therapeutics’ Arte...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The Imugene Limited (ASX: IMU) share price lifted 4% today after the company released its March quarter report. Imugene shares gained half a cent and were swapping hands at 13 cents in earlier trade but have since returned to their closing...

Today marked the penultimate day of March quarterly reports, and it appears to have pushed the materials sector up by half a per cent. Golden State Mining (GSM) was one of the many companies to release its results, and the market reacted...

Imugene’s (IMU) spent the March quarter continuing the development of its cancer-killing virus, VAXINIA IMU recently dosed the first patients in a combination and monotherapy trial of the drug after receiving ethics approval early in the...

Amid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught the eye of investors after some promising clinical news. These companies are working on so-called CAR-T therapies, which work by ‘superchar...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Imugene is developing immune-oncology to treat a range of cancers. Imugene (ASX: IMU) has more cash in the bank to pursue ongoing development of its immuno-oncology t...

Highlights Imugene has received its R&D tax refund of nearly AU$12.6 million for FY22. The Australian Government has provided the tax refund to IMU as part of its R&D tax incentive. IMU will use the refund amount to take forwa...

Imugene (IMU) presents positive imaging data from its viral drug oncolytic virotherapy candidate, CHECKvacc (CF33-hNIS-antiPDL1) SPECT data reveals potential local viral replication post-injection with resulting hNIS (human sodium iodide...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Clinical stage immune-oncology company Imugene (ASX: IMU) has revealed what it describes as positive imaging data on its oncolytic virotherapy candidate CHECKvacc in...

Highlights Imugene has presented positive imaging data on its oncolytic virotherapy candidate, CHECKvacc (CF33-hNIS-antiPDL1) at the AACR Annual Meeting 2023 in Orlando, Florida. The data was presented by Dr Jamie Rand, an Assistant Pr...

Local share will open flattish, tracking movements in New York Tesla’s profit margins plunge after aggressive cost cutting The RBA could be stripped of its interest rates setting powers   The ASX is poised to open flattish again on Thursd...

This ASX rare earths stock is exploding on the market today amid new drilling results. Larvotto Resources Ltd (ASX: LRV) shares soared 107% from 13.5 to 28 cents today before slightly retreating. The company’s share price is still up 85%...

When it comes to ASX lithium stocks, Nova Minerals Ltd (ASX: NVA) is probably not a share that initially comes to mind. But Nova Minerals is a $74 million company that has been listed on the ASX for more than two decades. It is primarily a...

Most index exchange-traded funds (ETFs) on the ASX work in a similar way. The fund tracks a single index, perhaps the S&P/ASX 200 Index (ASX: XJO), and by doing so, holds every share that the index tracks in the correct proportion. But...

The Imugene Ltd (ASX: IMU) share price has been racing ahead in the last month. Shares in the ASX 200 healthcare stock have risen 14.6% since market close on 17 March and are currently fetching 13.75 cents a share. For perspective, the S&...

The S&P/ASX 200 Index (ASX: XJO) spent the day in the green on Monday, rising 0.27% to close at 7,381.5 points. That was despite a disappointing Friday session on Wall Street. The Dow Jones Industrial Average Index (DJX: .DJI) ended l...

After wobbling in and out of the green this morning, the S&P/ASX 200 Index (ASX: XJO) cemented its position in the red on Thursday, closing the session 0.27% lower at 7,324.1 points. It followed a weak session on Wall Street overnight....

The S&P/ASX 200 Index (ASX: XJO) traded in the red ahead of the Easter long weekend, falling 0.25% to close Thursday’s session at 7,219 points. That left it 0.57% higher week-on-week. Weighing heaviest was the S&P/ASX 200 Inform...

The S&P/ASX 200 Index (ASX: XJO) put on a rocky performance on Wednesday, eventually closing the session 0.02% higher at 7,237.2 points. The fall came as Reserve Bank of Australia (RBA) governor Philip Lowe addressed the National Pres...

Red 5 (RED) has logged its strongest month of production to date. In March, more than 17,000 ounces of gold was produced from the company’s King of the Hills gold mine in Western Australia. RED shares were trading above 16 cents as go...

This content is created by Smallcaps Authors. [Author : Danica Cullinane] Clinical stage immune-oncology company Imugene (ASX: IMU) has announced it has started dosing a third cohort of patients in the intravenous (IV) and intratumoral (I...

Imugene (IMU) doses its first patients in the intravenous and intratumoral arms in cohort three of the monotherapy dose escalation trial The company’s phase one MAST study is evaluating the safety of cancer-killing virus CF33-hNIS (VAXI...

Highlights Imugene has dosed first patients in the intravenous and intratumoral arms in cohort 3 of the monotherapy dose escalation trial of its Phase 1 MAST study. A maximum of 100 patients will be recruited across 10 trial sites in A...

The S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.78% in Friday’s session to close at 7,177.8 points. That leaves it 3.2% higher week-on-week. And many of its top performers were mining stocks. The S&P/ASX 200...

The S&P/ASX 200 Index (ASX: XJO) slipped lower on Friday, falling 0.19% to close at 6,955.2 points. That leaves the index 0.57% lower week on week. It came on the back of rate hikes in the United Kingdom, Switzerland, and Norway overni...

The S&P/ASX 200 Index (ASX: XJO) recovered some of its Monday losses today, closing Tuesday’s session 0.82% higher at 6,955.4 points. The Aussie bourse’s day in the green followed a strong night’s trade over on Wall Street. The...

ShareCafeBig gains from Tech push ASX 0.86% higher by Peter Milios   The Australian stock market experienced a 0.89 per cent increase, reaching 7068.9 points, mainly due to growth in the technology industry. Link Administration (ASX:LNK) ha...

The share market surged to a two-week high after the Reserve Bank softened its interest rates guidance after raising the cash rate target for a record tenth straight time and suggesting inflation has peaked. Stocks popped and the dollar...

Aussie shares hovered near a two-week high in cautious trade ahead of this afternoon’s RBA interest rate announcement. Declines in mining and tech stocks helped ease the S&P/ASX 200 down two points or 0.02 per cent. Gains in supermar...

This content is created by Smallcaps Authors. [Author : Danica Cullinane] Immuno-oncology company Imugene (ASX: IMU) has collared a patent in the United States for its PD1-Vaxx immunotherapy for lung cancer, while clinical trials of its n...

Cancer cure researcher Imugene has announced that the first patients for its Phase 1 vaxinia combination trial have been dosed, kick-starting the all-important process of determining compatibility of vaxinia with pembrolizumab. The post Imu...

Imugene (IMU) doses the first patients in a combination study to test its cancer-killing virus, VAXINIA, along with antibody cancer drug Pembrolizumab The patients were dosed intravenously (IV) and intratumorally (IT) as part of IMU’s Ph...

Highlights Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving dosing in the intratumoral (IT) and intravenous (IV) cohorts of CF33-hNIS in combination with Pembrolizumab. The study is focused on measu...

The S&P/ASX 200 Index (ASX: XJO) ended the week in the red, falling 0.86% on Friday to close at 7,346.8 points. That leaves it down 1.17% week-on-week. Today’s tumble followed an equally disappointing overnight session on Wall Street...

The Treasury Wine Estates Ltd (ASX: TWE) share price is on the slide on Wednesday morning. At the time of writing, the wine giant’s shares are down 7% to $13.33. This follows the release of the company’s half year results. Treasury Win...

The Appen Ltd (ASX: APX) share price has been in a bit of a sorry state for a while now. Appen shares have dived today, for one. The All Ords tech share is currently down by a nasty 3.91% at $2.70 a share so far this Tuesday. But Appen’s w...

ShareCafeEnergy’s efforts are not enough to lift the ASX by Peter Milios   The ASX 200 index fell by 0.2 per cent to 7417.8 today, due to a decrease in the consumer discretionary sector. However, Energy closed 1.78 per cent higher as Russia...

ASX artificial intelligence (AI) stocks haven’t had a great run over the past 12 months. To say the least. Atop some company-specific issues, AI companies came under selling pressure as global interest rates shot up from historic lows to...

The Appen Ltd (ASX: APX) share price is taking a tumble, down 9.9% in Monday morning trade. The artificial intelligence (AI) data services company saw its shares rocket last week, gaining 28% over the past four trading days. With no price-...

The Endeavour Group Ltd (ASX: EDV) share price is charging ahead after the company dropped its earnings for the first half of financial year 2023 this morning. Shares in the drinks retailer and hotel operator are trading 4.69% higher at $7...

There are plenty of blue chip ASX 200 shares to choose from on the Australian share market. But three of the best, according to Morgans, are listed below. Here’s why the broker thinks highly of these blue chips: Treasury Wine Estates Lt...

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a disappointing note. The benchmark index fell 0.75% to 7,433.7 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 20...

ShareCafeASX closes 0.8% lower as UBS lift their cash rate peak forecast by Peter Milios   UBS Chief Economist George Tharenou has revised his peak cash rate forecast to 3.85 per cent in mid-2023, up from a previous forecast of 3.35 per cen...

The S&P/ASX 200 Index (ASX: XJO) ended the week just the way it started it – in the red. The index closed Friday’s session 0.76% lower at 7,433.7 points, marking a 1.65% week-on-week fall. It came as the Reserve Bank of Australia i...

Reporting from Sydney this morning, clinical-stage cancer immunotherapy developer Imugene [ASX:IMU] made the upbeat announcement that it now has a patent to treat patients in the US. A Notice of Allowance from the US Patent and Trademark Of...

The share market’s sparkling start to the year lost some of its fizz as the threat of higher interest rates dragged the Australian benchmark to its first losing week of 2023. The S&P/ASX 200 slid 56.6 points or 0.76 per cent this aft...

Shares fall to a three-week low amid RBA's 'hawkish' update. CBA says rate cut needed by end of year to avoid 'hard landing'. Allkem CFO dies of illness. Imugene soars on patent approval.

The share market slumped to a two-and-a-half week low as financial markets continued to adjust their expectations for the top of this interest rate cycle. The S&P/ASX 200 declined 51 points or 0.68 per cent by mid-session. The fall k...

ShareCafeASX down at noon despite RBA comments that inflation has likely peaked by Peter Milios   The Reserve Bank of Australia has revised its inflation forecasts, stating that the rapidly rising prices in the country have probably peaked....